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Introduction: Amyloid beta 1-43 (Aβ43), with its additional C-terminal threonine residue,
is hypothesized to play a role in early Alzheimer’s disease pathology possibly different
from that of amyloid beta 1-42 (Aβ42). Cerebrospinal fluid (CSF) Aβ43 has been
suggested as a potential novel biomarker for predicting conversion from mild cognitive
impairment (MCI) to dementia in Alzheimer’s disease. However, the relationship between
CSF Aβ43 and established imaging biomarkers of Alzheimer’s disease has never been
assessed.
Materials and Methods: In this observational study, CSF Aβ43 was measured with
ELISA in 89 subjects; 34 with subjective cognitive decline (SCD), 51 with MCI, and
four with resolution of previous cognitive complaints. All subjects underwent structural
MRI; 40 subjects on a 3T and 50 on a 1.5T scanner. Forty subjects, including 24 with
SCD and 12 with MCI, underwent 18F-Flutemetamol PET. Seventy-eight subjects were
assessed with 18F-fluorodeoxyglucose PET (21 SCD/7 MCI and 11 SCD/39 MCI on two
different scanners). Ten subjects with SCD and 39 with MCI also underwent diffusion
tensor imaging.
Results: Cerebrospinal fluid Aβ43 was both alone and together with p-tau a significant
predictor of the distinction between SCD and MCI. There was a marked difference in
CSF Aβ43 between subjects with 18F-Flutemetamol PET scans visually interpreted as
negative (37 pg/ml, n = 27) and positive (15 pg/ml, n = 9), p < 0.001. Both CSF
Aβ43 and Aβ42 were negatively correlated with standardized uptake value ratios for all
analyzed regions; CSF Aβ43 average rho −0.73, Aβ42 −0.74. Both CSF Aβ peptides
correlated significantly with hippocampal volume, inferior parietal and frontal cortical
thickness and axial diffusivity in the corticospinal tract. There was a trend toward CSF
Aβ42 being better correlated with cortical glucose metabolism. None of the studied
correlations between CSF Aβ43/42 and imaging biomarkers were significantly different
for the two Aβ peptides when controlling for multiple testing.
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Conclusion: Cerebrospinal fluid Aβ43 appears to be strongly correlated with cerebral
amyloid deposits in the same way as Aβ42, even in non-demented patients with only
subjective cognitive complaints. Regarding imaging biomarkers, there is no evidence
from the present study that CSF Aβ43 performs better than the classical CSF biomarker
Aβ42 for distinguishing SCD and MCI.
Keywords: Alzheimer’s disease, amyloid beta 1-43, cerebrospinal fluid, positron emission tomography, magnetic
resonance imaging, mild cognitive impairment
INTRODUCTION
Alzheimer’s disease (AD) is the leading cause of dementia.
Treatment of this devastating disease will depend on biomarkers
that can reliably identify individuals who will develop dementia
due to AD in the future. A previous study following patients
with mild cognitive impairment (MCI) for 2 years, found that
the baseline cerebrospinal fluid (CSF) levels of amyloid-beta 1-43
(Aβ43) could distinguish patients that converted to AD dementia
from those that did not, suggesting that CSF Aβ43 could be a
useful addition to the more well-studied CSF biomarkers amyloid
beta 1-42 (Aβ42), total tau (t-tau), and tau phosphorylated on
position 181 (p-tau) (Kandimalla et al., 2011, 2013; Lauridsen
et al., 2016). Aβ43 differs from Aβ42 by one C-terminal threonine
residue, and is the product of an alternative γ-secretase cleavage
pathway from the amyloid precursor protein (APP) (Takami
et al., 2009). Findings from studies of neuropathology, genetics
and animal models have resulted in the hypothesis that Aβ43
could play a role in AD pathogenesis out of proportion to its
low levels in the brain. With its additional C-terminal beta-
branched amino acid, Aβ43 could theoretically be expected to
be more prone to aggregation than Aβ42. Experiments in vitro
have yielded conflicting results: some report that Aβ43 indeed
aggregates faster than Aβ42 and with a higher potential for
seeding aggregation of other Aβ species (Saito et al., 2011;
Conicella and Fawzi, 2014), others that Aβ43 aggregates slower
with later amyloid nucleation and that it is inefficient in cross-
seeding Aβ42 (Chemuru et al., 2016). Whether these experiments
reflect the true aggregational process in the human brain is
uncertain (Vandersteen et al., 2012). Cerebral deposition of Aβ43
is frequently present both in sporadic and familial AD (Welander
et al., 2009; Keller et al., 2010; Sandebring et al., 2013) as a
component of both neuritic and diffuse extracellular plaques
(Iizuka et al., 1995; Parvathy et al., 2001; Miravalle et al., 2005).
Some PSEN1 mutations associated with familial AD are known
to cause an overproduction of Aβ43 (Nakaya et al., 2005; Shimojo
et al., 2008). In a transgenic mouse model based on such a
PSEN1 mutation, Aβ43 appeared to have greater neurotoxicity
than Aβ42 with short-term memory impairment occurring with
rising levels of Aβ43 even before plaque formation (Saito et al.,
2011). Aβ43 has also been shown to deposit ahead of Aβ42 in the
brain of mutant APP transgenic mice (Zou et al., 2013).
Information is sparse regarding CSF Aβ43 as a potential
clinical biomarker, especially in early stages of cognitive
impairment. Previously, it has been shown that CSF Aβ43
levels are decreased in MCI and AD dementia as compared
to controls, with a strong correlation between CSF levels
of Aβ43 and Aβ42 (Kakuda et al., 2012; Lauridsen et al.,
2016). At the late stage of dementia, CSF Aβ43 and Aβ42
appear to have equal diagnostic accuracy for discriminating
AD dementia from non-demented controls (Bruggink et al.,
2013). Clinically more important, however, is the ability of
biomarkers to single out non-demented patients that are on a
trajectory toward AD dementia. A meta-analysis combining the
classical CSF biomarkers; Aβ42 with t-tau and/or p-tau, yielded
a mean sensitivity of 84% and a mean specificity of 63% for
the distinction between stable and progressive MCI (Ferreira
et al., 2014). Enhancement of this diagnostic performance would
obviously be an advantage. Lauridsen et al. (2016) found that
when used in a ratio with t-tau, substituting Aβ42 with Aβ43
gave a slight, but significant improvement of the diagnostic
accuracy for this distinction, a finding that warrants further
exploration. The use of CSF biomarkers in clinical routine is
impeded by the invasiveness of lumbar puncture and by the
high between-center variability particularly in the measurement
of Aβ42. Imaging biomarkers are often more readily available,
provide complimentary information as well as improve the
predictive accuracy for dementia conversion when combined
with CSF biomarkers (Vemuri et al., 2009). To our knowledge,
CSF Aβ43 has not been described in relation to imaging
biomarkers.
Positron emission tomography (PET) imaging allows
visualization of cerebral Aβ aggregates in vivo. Uptake of
amyloid-binding PET tracers, like 18F-Flutemetamol (18F-
FLUT), correlates inversely with CSF Aβ42 levels (Fagan et al.,
2006; Li et al., 2015), and positively with Aβ plaque burden
observed post-mortem (Ikonomovic et al., 2008). It remains
to be determined whether the relationship with amyloid PET
is the same for CSF Aβ43. In addition to amyloid pathology,
development of AD is characterized by neurodegeneration.
Neurodegenerative changes in AD identifiable by magnetic
resonance imaging (MRI) include gray matter atrophy of the
hippocampus and vulnerable cortical regions (Whitwell et al.,
2008; Sabuncu et al., 2011), and microstructural white matter
changes resulting in increased mean, radial and axial diffusivity
and reduced fractional anisotropy on diffusion tensor imaging
(DTI) (Selnes et al., 2013; Amlien and Fjell, 2014; Lee et al.,
2015). Several studies have reported correlations between
CSF Aβ42 and structural MRI, while others have found no
association, with methodological differences suggested as a
possible reason for the discrepancy (Vemuri and Jack, 2010;
Li et al., 2014). Neurodegeneration is also related to changes
in cerebral metabolism as assessed by 18F-fluorodeoxyglucose
(18F-FDG) PET imaging (Fouquet et al., 2009). In AD dementia
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cortical 18F-FDG uptake has been reported to correlate with CSF
Aβ42 levels (Vukovich et al., 2009; Yakushev et al., 2012) and
18F-FDG PET imaging appears to have high prognostic value in
MCI (Shaffer et al., 2013; Perani et al., 2016).
The objectives of this study were to explore firstly whether
CSF Aβ43 reflects cerebral amyloid deposits as visualized by
18F-FLUT PET, and secondly whether CSF Aβ43 correlates with
MRI and 18F-FDG PET imaging findings of neurodegeneration
in non-demented patients with cognitive complaints.
MATERIALS AND METHODS
Subject Recruitment
Cohort 1 – Amyloid PET cohort:
Forty subjects were included in the Dementia Disease Initiation
(DDI) project at Akershus University Hospital between March
2013 and March 2016. They were referred by their general
practitioner to the hospital’s memory clinic or recruited
through newspaper advertisements. Inclusion criteria were
complaints of decline in cognitive capacity compared with
a previously normal state, age 40–79 and Scandinavian
first language. Exclusion criteria were established dementia,
neurodevelopmental disorders, known brain injury including
recognized previous stroke, as well as any serious somatic
or psychiatric disorder or drug use that could significantly
influence cognitive capacity. All subjects were assessed with
18F-FLUT PET either at the time of inclusion (n = 22) or
at a second assessment 2 years after first inclusion in the
project (n = 18). Clinical assessment, lumbar puncture, and
MRI were done within 3.5 months of 18F-FLUT PET. Thirty-
one of the 40 subjects also underwent 18F-FDG PET. Patients
were interviewed and examined by a physician trained in
diagnosing cognitive disorders. A clinical report form was
used to collect information about current cognitive symptoms
both from the participant and a knowledgeable informant.
Standardized cognitive testing, physical examination, and blood
screening were completed. MCI (n = 12) was defined based
on the core criteria in the recommendation from the National
Institute on Aging-Alzheimer’s Association (NIA/AA; Albert
et al., 2011). Documented impairment greater than expected
for the person’s age, gender, and educational level in one or
more cognitive domains was operationalized by a score 1.5
standard deviations or more below the normative mean on
at least one of the following tests; the delayed recall task of
the CERAD Word List Test (Fillenbaum et al., 2008), Trail
Making Test B (TMTB) (Reitan and Wolfson, 1985), Controlled
Oral Word Association Test (COWAT) (Benton and Hamsher,
1989) and the silhouettes task from the Visual Object and Space
Perception (VOSP) Battery (Warrington and James, 1991) or a
score below 28 on MMSE (Folstein et al., 1975). All subjects
maintained independent functioning in social, and if appropriate,
occupational settings, and had a global Clinical Dementia Rating
score of ≤0.5 (Morris, 1997). Subjective cognitive decline (SCD)
(n = 24) was defined according to the recommendations by the
Subjective Cognitive Decline Initiative Working Group (Jessen
et al., 2014), with normal performance on standardized cognitive
tests operationalized by a score above 1.5 standard deviations
below the normative mean on the above mentioned tests. Four
subjects had been classified as having SCD at inclusion, but did
not have cognitive complaints 2 years later when they underwent
18F-FLUT PET. They had normal performance on cognitive
tests and were classified as cognitively normal with resolution of
previous cognitive complaints (CN).
Cohort 2 – MRI and DTI cohort:
Fifty subjects were included in the MCI project at Akershus
University Hospital between January 2007 and February 2013
after having been referred to the hospital’s memory clinic by their
general practitioner. Inclusion criteria were cognitive complaints
for at least 6 months and age 40–79. Exclusion criteria included
established dementia, major psychiatric disorder, drug abuse,
significant solvent exposure, and anoxic brain damage. All
subjects underwent lumbar puncture and MRI at inclusion. The
subjects were assessed with clinical interview, routine physical
examination, blood screening, and a battery of cognitive tests.
One subject was found to have been included in Cohort 1 and was
therefore excluded from Cohort 2 when data from both cohorts
were analyzed together (total number of unique subjects in the
study n = 89). Subjects in Cohort 2 were defined as having MCI
(n= 39) if objective cognitive impairment was evident on at least
one of the following screening tests; MMSE score below 28, score
equivalent to mild impairment on one or more of the items of
the Cognistat (Kiernan et al., 1987) or score >1 on I-Flex (Royall
et al., 1992). Subjects without objective cognitive impairment
on the same screening battery were classified as having SCD
(n= 11).
Ethics Statement
The study was conducted in accordance with the Helsinki
Declaration. All participants gave written informed consent. The
Regional Committee for Medical and Health Research Ethics,
South East Norway, approved the study (approval 2009/2550 and
2013/150).
CSF Collection and Storage
Lumbar puncture was performed generally between 8 a.m. and
noon, at the L3/L4, L4/L5, or L5/S1 interspace and without any
serious adverse events. The first 4 ml CSF was used for routine
clinical investigations. The next 1.5 and 4.5 ml CSF were collected
in two polypropylene tubes and centrifuged at 2000 × g for
10 min within 4 h of collection. The 1.5 ml CSF was stored at
−80◦C prior to analysis of the traditional CSF biomarkers Aβ42,
t-tau and p-tau. In Cohort 1, the 4.5 ml CSF was aliquoted into
450 µl polypropylene tubes before storage at −80◦C, while in
Cohort 2 the 4.5 ml CSF was stored at −80◦C, before later being
thawed and aliquoted, with further storage at −80◦C prior to
determination of Aβ43. Consequently, the samples underwent
one freeze-thaw cycle before determination of Aβ43 in Cohort
1 and two in Cohort 2, with the exception of two samples in
Cohort 2 where due to lack of CSF in the biobank, remaining CSF
after analysis of the traditional CSF biomarkers was used also for
analysis of Aβ43, resulting in three freeze-thaw cycles.
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ELISA Assays and APOE Genotyping
Cerebrospinal fluid levels of Aβ42, t-tau, and p-tau were
quantified with commercially available ELISAs; Innotest R©
β-amyloid 1–42 (Vanderstichele et al., 2000), Innotest R©
hTau Ag (Blennow et al., 1995), and Innotest R© phosphoTau
(181P) (Vanmechelen et al., 2000) (Fujirebio Europe, Gent,
Belgium), and carried out in accordance with the manufacturers’
instructions at the national reference laboratory for these tests
at the Department of Interdisciplinary Laboratory Medicine
and Medical Biochemistry, Akershus University Hospital. The
laboratory lists the following cut-off values for abnormality
(modified from Sjögren et al., 2001); t-tau > 300 pg/ml
for age < 50 years, >450 pg/ml for age 50–69 years, and
>500 pg/ml for age ≥ 70 years, p-tau ≥ 80 pg/ml and
Aβ42 < 550 pg/ml.
Aβ43 in CSF was analyzed at the laboratory of the
Department of Neuroscience, Norwegian University of Science
and Technology, Trondheim, Norway, with an ELISA monoplex
kit; Aβ1-43, RE59711 (IBL, Hamburg, Germany) run according
to the instructions given by the manufacturer. The antibodies
included in the kit were anti-human Aβ (38–43) rabbit IgG
affinity purity and anti-human Aβ (82E1) mouse IgG MoAb Fab’
affinity purity. According to the manufacturers of the kits the
cross-reactivity for Aβ42 in the Aβ43 ELISA is <1% and the
antibodies in the Innotest R© β-amyloid 1–42 have 50x less affinity
for Aβ43 compared to Aβ42. Samples of CSF were analyzed
undiluted and in duplicate. The measurement range for the kit
was reported to be 2.34–150 pg/ml. All samples analyzed in the
study (7.51–66.49 pg/ml) fell within this range. Intra- and inter-
assay variations have been reported previously (Lauridsen et al.,
2016). As this study continued from the previously published
material, these values were not calculated again.
Apolipoprotein E (APOE) genotyping was performed on
EDTA blood samples from all subjects at the Gene Technology
Division, Department of Interdisciplinary Laboratory Medicine
and Medical Biochemistry, Akershus University Hospital
according to the laboratory’s routine protocol using real-time
PCR combined with a TaqMan assay (Applied Biosystems,
Thermo Fisher Scientific, Waltham, MA, USA).
MRI Imaging Acquisition and Processing
In Cohort 1, MRI scans were acquired on a Philips Achieva 3
Tesla system. A single 3D turbo field echo sequence was acquired
for morphometric analysis with the following sequence
parameters: TR/TE/TI/FA = 4.5 ms/2.2 ms/853 ms/8◦,
matrix = 256 × 213, 170 slices, thickness = 1.2 mm,
in-plane resolution of 1 mm × 1.2 mm. In Cohort 2,
MRI was performed on a Siemens Espree 1.5 T scanner.
One 3D magnetization-prepared rapid gradient echo
T1-weighted sequence was obtained with the following
specifications: TR/TE/TI/FA = 2400 ms/3.65 ms/1000 ms/8◦,
matrix = 240 × 192, 160 slices, thickness = 1.2 mm, in-plane
resolution of 1 mm × 1.2 mm. The pulse sequence used
for DTI was: b = 750, 12 directions repeated five times, five
b0-values per slice, TR = 6100 ms, TE = 117 ms, number of
slices = 30, slice thickness = 3 mm (gap = 1.9 mm), in-plane
resolution= 1.2× 1.2 mm2, bandwidth= 840 Hz/pixel. Cortical
reconstruction and volumetric segmentation was performed
with the FreeSurfer image analysis suite version 5.3.01. This
includes segmentation of the subcortical white matter and
deep gray matter volumetric structures (Fischl et al., 2002)
and parcellation of the cortical surface (Fischl et al., 2004)
according to a previously published scheme labeling cortical
sulci and gyri (Desikan et al., 2006), and thickness values are
calculated over the cortical mantle. The thickness value of the
entorhinal cortex (ERC) was calculated using a method based
on ultra-high resolution ex vivo applied to in vivo MRI, as
implemented in FreeSurfer (Fischl et al., 2009). In addition to
hippocampal volume and cortical thickness of the ERC, the
thickness of the following cortical regions of interest (ROIs)
known to be atrophic relatively early in the development of AD
were selected for analysis; the temporopolar, middle temporal,
posterior cingulate, inferior parietal, and inferior frontal cortex.
For analyses of the total hippocampal volume, the sum of the
right and left hippocampal volumes as permillage (h) of the
estimated total intracranial volume was used. For each cortical
ROI, the average of the measurements from the right and
left hemisphere was used. Image processing for DTI has been
described previously (Kalheim et al., 2016). DTI data were
missing for one subject (n = 49). The fractional anisotropy,
mean, radial, and axial diffusivities were assessed in the following
four tracts, selected based on previous reports of DTI changes
in AD and MCI (Amlien and Fjell, 2014; Lee et al., 2015) and
calculated as an average of the metrics from the right and left
hemispheres; the cingulum bundles (average of the cingulum-
cingulate gyrus bundle and the cingulum-angular bundle), the
corpus callosum-forceps bundles (average of the corpus callosum
bundles to forceps major and minor, respectively), the uncinate
fasciculus and the corticospinal tract.
PET Imaging Acquisition, Processing,
and Interpretation
In Cohort 1 18F-FLUT and 18F-FDG PET/CT imaging were
performed on the same GE Discovery 690 PET/CT scanner
on two separate days. Subjects received a bolus injection of
185 MBq (5 mCi) tracer and after resting were positioned head-
first supine in the scanner. A low-dose CT scan was acquired
first for attenuation correction. Subjects fasted at least 6 h in
advance and blood glucose was measured routinely before 18F-
FDG injection (all subjects had blood glucose below 8.0 mmol/l).
PET scanning in 3D-mode commenced 45 min after injection of
18F-FDG and 90 min after 18F-FLUT. PET data were acquired
for 10 min for 18F-FDG and for 20 min (four frames of 5 min)
for 18F-FLUT. Acquired data were corrected for random events,
dead time, attenuation, scatter, and decay. PET volumes were
reconstructed with an iterative algorithm (VUE Point FX SharpIR
with six iterations, 24 subsets for 18F-FDG, four iterations, 16
subsets for 18F-FLUT) and smoothed with a post-reconstruction
3D Gaussian filter of 3 mm full-width at half maximum. Image
format for 18F-FDG was 256 × 256 (pixel size 1 mm × 1 mm),
for 18F-FLUT 192× 192 (pixel size 1.3 mm× 1.3 mm), with slice
1http://surfer.nmr.mgh.harvard.edu/
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thickness 3.75 mm. In Cohort 2 18F-FDG PET/CT-scans were
acquired as previously described (Coello et al., 2013).
Visual interpretation of the 18F-FLUT images was done
by trained readers and the scans were classified as positive
or negative in line with the manufacturer’s guidelines. For
the automated quantitative assessment, motion correction of
the dynamic 18F-FLUT PET was performed using frame by
frame rigid registration, then the frames were summed to
a single time-frame image and registered to the anatomical
MRI volume using a six-parameter rigid registration as
implemented in the Spatial Parametrical Mapping (SPM 12,
Wellcome Trust Centre for Neuroimaging, UCL, UK) toolbox.
Due to missing dynamic images one subject had to be
excluded from the automated quantitative analyses (n = 39).
Five cortical ROIs known to harbor substantial amyloid
plaques in AD were selected for analysis of 18F-FLUT uptake:
the precuneus and posterior cingulate combined, anterior
cingulate, prefrontal, inferior parietal and lateral temporal
cortex. The average 18F-FLUT uptake in each of these ROIs
was calculated incorporating values from both hemispheres.
The average uptake in the cerebellar cortex, which is usually
devoid of amyloid pathology in early AD, was used as the
reference region after eroding voxels at the segmentation
boundaries to avoid influence due to inaccurate segmentation
or co-registration. Regional standardized uptake value ratios
(SUVRs) for 18F-FLUT were created by dividing the average
uptake in each ROI by the average uptake in the cerebellar
cortex.
The same ROIs that were used for the structural MRI analyses
were selected for study of 18F-FDG activity. Uptake in the
cerebellar white matter was used as the reference region after
first eroding the cerebellar white matter mask. SUVRs were
calculated by dividing the average uptake of 18F-FDG per voxel
in each ROI to the average uptake in the cerebellar white
matter.
Statistical Analysis
The statistical analyses were performed using IBM SPSS version
23 (Chicago, IL, USA) unless otherwise stated. All tests were
two-sided and p-values below 0.05 were considered significant.
Distribution of the variables and whether normal distribution
could be assumed were assessed by histograms and a Shapiro–
Wilk test. Levene’s statistics were calculated to assess the
homogeneity of variance in each variable for parametric tests.
For comparisons of CSF biomarker levels, demographical data
and neuropsychological test results between SCD and MCI, a χ2
test was used for categorical variables, an independent sample
t-test for continuous variables with normal distribution, and a
Mann–Whitney U test for continuous variables with non-normal
distribution. Binary logistic regression models were created with
the SCD/MCI distinction as the dependent variable and with
either CSF tau, p-tau or one of the imaging biomarkers as a
covariate. In significant models, CSF Aβ43 and Aβ42 were then
in turn added as a second covariate. Bivariate correlation and
partial correlation controlling for age were assessed between CSF
biomarkers, MRI, 18F-FLUT and 18F-FDG variables. Spearman’s
rank coefficients (rho) of the correlations between an imaging
variable and Aβ43, and the imaging variable and Aβ42, were
compared with an asymptotic z test using software available
from http://quantpsy.org (Lee and Preacher, 2013). To detect
potential interrelating effects of aging, all analyses were done
both unadjusted and with age as a covariate. Controlling for
gender and educational length was not done, as these factors
were not found to have significant impact in linear regression
models of imaging measures as a function of Aβ. APOE genotype
was related to CSF Aβ43 levels, but was not found to be a
significant factor in regression models that already included
either Aβ42 or Aβ43, and was therefore not included as a
covariate. Differences in baseline CSF Aβ43 and Aβ42 levels
between groups based on the result of the 18F-FLUT PET were
assessed using an independent samples t-test. Receiver operating
characteristic (ROC) curves for the prediction of a positive 18F-
FLUT scan were plotted for both Aβ peptides, and area under the
curve (AUC) was calculated. Cut-off values for Aβ43 and Aβ42
yielding the best combination of sensitivity and specificity, were
determined by maximal Youden’s index. Differences in AUC were
assessed using MedCalc statistical software (MedCalc software,
Mariakerke, Belgium).
RESULTS
Demographics, Cognition, and CSF
Biomarkers: Comparison between SCD
and MCI
Demographical characteristics, cognitive scores and CSF
biomarker levels in the SCD and MCI groups are reported in
Table 1. The frequency of the APOEε4 genotype was similar in
both SCD and MCI. The pattern of relative levels of the two
CSF Aβ peptides was similar with respect to APOE genotype,
with significantly lower mean peptide levels in the group
with APOEε4/ε4 (Figure 1). No significant difference for the
correlations between APOE allele and Aβ43 and Aβ42 levels
was found. There was a strong positive correlation between
the CSF measurements of Aβ43 and Aβ42 (all subjects rho
0.88, p < 0.001) with no significant difference between the
groups (SCD rho 0.81 and MCI rho 0.86). In the MCI group
both Aβ43 and Aβ42 correlated inversely with t-tau and p-tau
without any significant difference between the two amyloid
peptides (MCI n = 51, Aβ43:t-tau rho −0.45, p = 0.001, Aβ42:t-
tau rho −0.35, p = 0.01, Aβ43:p-tau rho −0.38, p = 0.007,
Aβ42:p-tau rho −0.40, p = 0.003). In the SCD group, however,
there were no significant correlations between Aβ43/Aβ42
and t-tau and p-tau. For all subjects (n = 89) the overall
correlation coefficients for Aβ43:t-tau was rho −0.28, Aβ42:t-tau
rho −0.25, Aβ43:p-tau rho −0.29, and for Aβ42:p-tau rho
−0.37, without any significant differences between Aβ43 and
Aβ42. Adjustment for age did not significantly change the
correlations between the CSF biomarkers. In binary logistic
regression models for the distinction between SCD and MCI,
both Aβ43, Aβ42, and p-tau were statistically significant
predictors when entered into the model as the only CSF
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TABLE 1 | Demographics, cognitive scores, and cerebrospinal fluid (CSF) biomarkers in SCD and MCI.
SCD MCI p
n 34 51
Gender m/f, n 15/19 22/29 –
Age 64.5 [9] 65 [10] –
Years of education 14 [4] 14 [5] –
APOEε4 (%) 47 45 –
MMSE total score 29 [1] 28 [2] <0.001
RAVLT delayed recall t-score 57 [20] 47 [18] <0.001
TMT B t-score 49 [9] 44 [11] 0.005
COWAT t-score 52 [13] 49 [16] –
CSF Aβ43 pg/ml 37 [22] 24 [19] 0.004
CSF Aβ42 pg/ml (% below cut-off) 981 [488] (12) 679 [388] (26) 0.009 (0.17)
CSF t-tau pg/ml (% above cut-off) 312 [155] (6) 335 [267] (31) 0.13 (0.006)
CSF p-tau pg/ml (% above cut-off) 57 [25] (6) 69 [34] (35) 0.001 (0.003)
Data are presented as the median [interquartile range], unless otherwise stated. The cut-off values for CSF Aβ42, t-tau, and p-tau are those of the national reference
laboratory: Aβ42 < 550 pg/mL, p-tau ≥ 80 pg/mL, and t-tau > 300 pg/mL for age < 50 years, >450 pg/mL for age 50–69 years, and >500 pg/mL for age ≥ 70 years.
APOEε4 is presented as the percentage of subjects with at least one ε4-allele. The scores on TMTB, COWAT, and RAVLT were missing for one subject in Cohort 2.
“–” p-value > 0.15. RAVLT, Rey Auditory Verbal Learning Test (Schmidt, 1996); TMT B, Trail Making Test B; COWAT, Controlled Oral Word Association Test; MCI, Mild
cognitive impairment; SCD, subjective cognitive decline; APOE, Apolipoprotein E genotype.
biomarker. In a multivariate model with p-tau, inclusion of
Aβ43 added significantly to the prediction, while Aβ42 did not
(Table 2).
Amyloid PET
Based on visual interpretation nine of the 40 18F-FLUT PET scans
were deemed to be positive (five SCD, four MCI), two borderline
positive (one CN and one MCI), two borderline negative (one
SCD and one MCI), and 27 negative (18 SCD, six MCI, three
CN). The mean CSF Aβ43 in these four groups were 15, 22,
32, and 37 pg/ml, respectively, and the mean CSF Aβ42 547,
657, 1074, and 1042 pg/ml. The mean difference [95% CI] in
CSF concentration between subjects with positive and negative
scans was 22 pg/ml [13,31] for Aβ43 and 495 pg/ml [380,611]
for Aβ42, p < 0.001 for both. ROC curves for prediction of a
positive scan gave AUC 0.97 for both Aβ43 and Aβ42. The best
cut-off value was ≤24 pg/ml for Aβ43 with sensitivity 100% and
specificity 93% for a positive scan, and≤679 pg/ml for Aβ42 with
sensitivity 100% and specificity 89%. In the group with negative
scans, 16/27 (59%) had APOE genotype APOEε3/ε3 and 9/27
(33%) APOEε3/ε4, the same in the group with positive scans was
2/9 (22%) and 5/9 (56%), but the differences were not statistically
significant. 18F-FLUT SUVR based on the automated quantitative
assessment of the scans was not a significant predictor of
the SCD/MCI distinction in binary logistic regression models
with and without age as a covariate. Mean overall 18F-FLUT
SUVR for the five ROIs was 1.29, 95% CI [1.17–1.40] in the
SCD group and 1.40, 95% CI [1.23–1.58] in the MCI group
(p = 0.26). There were highly significant inverse correlations
between CSF Aβ43 and 18F-FLUT SUVR in all the examined
ROIs and the correlations became stronger with adjustment for
the effect of age (Table 3). The same was true for Aβ42, and
there were no significant differences between the correlation
coefficients for the two Aβ peptides. The correlations with overall
18F-FLUT SUVR remained strong also when analyzing only
subjects diagnosed with SCD (n = 23; rho −0.64, p = 0.001
for both Aβ peptides, adjusted for age rho −0.69, p < 0.001 for
Aβ43, and rho −0.67, p = 0.001 for Aβ42). When excluding
subjects with visually interpreted definitely positive scans from
the analysis (n = 31), there were still significant correlations
with overall SUVR; for Aβ43 unadjusted rho −0.37, p = 0.04,
adjusted for age rho −0.52, p = 0.004, for Aβ42 unadjusted rho
−0.39, p = 0.03, adjusted for age rho -0.51, p = 0.004. CSF
t-tau and p-tau were not significantly correlated with overall
18F-FLUT SUVR (t-tau rho 0.29, p = 0.07, p-tau rho 0.24,
p= 0.15).
Hippocampal Volume and Cortical
Thickness
Magnetic resonance imaging data from the two cohorts were
analyzed separately due to the use of different scanners for the
imaging acquisition. There were no significant differences in
mean hippocampal volume or thickness in the six cortical ROIs
between SCD and MCI in either of the cohorts (Supplementary
Table) and none of the ROIs were significant predictors of
the SCD/MCI distinction in binary logistic regression models
even after adjustment for age. In Cohort 1 there were no
significant correlations between Aβ43/42 CSF levels and the
structural MRI measurements. In Cohort 2 there were unadjusted
moderate positive correlations for both CSF Aβ43 and Aβ42 with
total hippocampal volume, thickness of the middle temporal,
inferior parietal and inferior frontal cortices with statistical
significance after correction for multiple testing in seven
ROIs. CSF Aβ43 correlated significantly also with thickness
of the ERC and CSF Aβ42 with posterior cingulate cortical
thickness. After adjustment for effects of age, however, only
the correlations with hippocampal volume, inferior parietal and
inferior frontal cortical thickness were nominally significant
(Table 4). In the SCD group CSF Aβ43 correlated significantly
with hippocampal volume and CSF Aβ42 with thickness of the
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FIGURE 1 | Box-plots of cerebrospinal fluid (CSF) Aβ43 and Aβ42 according to APOE genotype. All subjects from both cohorts have been included, except
for one subject with genotype APOEε2/ε4. CSF Aβ43 for this subject was 17 pg/ml and CSF Aβ42 598 pg/ml. The whiskers represent the range, except for the two
outliers. There were significant differences in mean CSF Aβ43 and Aβ42 levels between the APOEε4/ε4-group and the three other groups (all p<0.01). APOE,
Apolipoprotein E genotype.
TABLE 2 | Specification of logistic regression models for the SCD/MCI distinction with one or two CSF biomarkers as covariates together with age.
Model χ2 Nagelkerke R2 Sensitivity Specificity OR p
Aβ43 10.2, p = 0.006 0.15 88% 50% 0.95 0.004
Aβ42 8.6, p = 0.01 0.13 88% 44% 0.998 0.008
p-tau 10.8, p = 0.005 0.16 80% 50% 1.03 0.008
t-tau 3.4, p = 0.18
p-tau + Aβ43 15.9, p = 0.001 0.23 84% 56% p-tau 1.03 0.03
Aβ43 0.96 0.03
p-tau + Aβ42 13.8, p = 0.003 0.20 88% 53% p-tau 1.02 0.04
Aβ42 0.998 0.09
OR, Odds ratio; MCI coded 1, SCD 0. n = 85.
TABLE 3 | Correlation analyses between 18F-FLUT SUVRs and Aβ43 or Aβ42 in CSF, unadjusted and adjusted for age.
Unadjusted Adjusted for age
Aβ43 Aβ42 Aβ43 Aβ42
Prefrontal SUVR −0.60∗∗ −0.64∗∗ −0.71∗∗ −0.73∗∗
Precuneus – Posterior cingulate SUVR −0.67∗∗ −0.70∗∗ −0.74∗∗ −0.75∗∗
Anterior cingulate SUVR −0.61∗∗ −0.67∗∗ −0.71∗∗ −0.75∗∗
Inferior parietal SUVR −0.65∗∗ −0.70∗∗ −0.72∗∗ −0.76∗∗
Lateral temporal SUVR −0.54∗ −0.59∗∗ −0.64∗∗ −0.67∗∗
Average of the five SUVRs −0.63∗∗ −0.67∗∗ −0.73∗∗ −0.74∗∗
Data presented are Spearman’s rank coefficients for correlations between 18F-FLUT SUVRs (standardized uptake value ratios) and CSF levels of Aβ43 and Aβ42,
respectively. Dynamic 18F-FLUT data were missing for one subject, n = 39. ∗Correlations with p-values < 0.001. ∗∗Correlations with p-values < 0.0001. There were no
statistically significant differences in correlation coefficients between CSF Aβ43 and Aβ42.
posterior cingulate cortex. In the MCI group there were no
significant correlations after correction for age. None of the
correlations were significantly different between CSF Aβ43 and
Aβ42, there was only a trend toward the correlation coefficient
for hippocampal volume being stronger with CSF Aβ43 than
Aβ42 (p = 0.05 unadjusted for age, p = 0.07 adjusted for age)
in the SCD group. Both CSF Aβ43 and Aβ42 were significant
predictors of hippocampal volume in linear regression both
with and without age in the model. T-tau was a significant
predictor when modeled alone and with age, but not when
either of the CSF Aβ peptides were entered into the same
model.
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TABLE 4 | Correlations between CSF Aβ43, CSF Aβ42, hippocampal volume, and cortical thickness in SCD and MCI subjects together or separately in
Cohort 2.
All SCD n = 11 MCI n = 39
Aβ43 Aβ42 Aβ43 Aβ42 Aβ43 Aβ42
Hippocampus volume,h 0.52∗∗ 0.52∗∗ 0.66∗ 0.26 0.51∗∗ 0.51∗∗
Age-adjusted 0.33∗ 0.30∗ 0.64∗ 0.29 0.28 0.25
Entorhinal cortex thickness 0.39∗∗ 0.29∗ 0.29 −0.05 0.35∗ 0.23
Age-adjusted 0.25 0.10 0.20 −0.09 0.23 0.07
Posterior cingulate cortex thickness 0.37∗ 0.39∗∗ 0.47 0.66∗ 0.23 0.28
Age-adjusted 0.22 0.23 0.43 0.72∗ 0.02 0.04
Temporopolar cortex thickness 0.20 0.27 0.29 0.17 0.13 0.24
Age-adjusted 0.05 0.12 0.24 0.17 −0.07 0.04
Middle temporal cortex thickness 0.46∗∗ 0.51∗∗ 0.52 0.34 0.43∗∗ 0.51∗∗
Age-adjusted 0.27 0.32∗ 0.49 0.39 0.18 0.26
Inferior parietal cortex thickness 0.50∗∗ 0.52∗∗ 0.55 0.45 0.47∗∗ 0.51∗∗
Age-adjusted 0.30∗ 0.29∗ 0.54 0.56 0.22 0.24
Inferior frontal cortex thickness 0.41∗∗ 0.41∗∗ 0.43 0.34 0.39∗ 0.40∗
Age-adjusted 0.32∗ 0.31∗ 0.42 0.34 0.25 0.24
Data presented are Spearman’s rank coefficients for bivariate correlation and partial correlation correcting for age. n = 50. ∗Nominal significance (p < 0.05), ∗∗Significant
correlations with correction for multiple testing in seven regions of interest (p < 0.05/7). None of the correlation coefficients were significantly different between CSF Aβ43
and Aβ42.
Diffusor Tensor Imaging
Diffusor tensor imaging was only available for Cohort 2. There
were no statistically significant differences in the DTI metrics
of the selected tracts between the SCD and MCI groups
and in logistic regression models none of the DTI metrics
were significant covariates for the SCD/MCI distinction even
after adjustment for age. Both CSF Aβ43 and Aβ42 were
inversely correlated with axial diffusivity in the corticospinal
tract and this was the only correlation that maintained
significance after correction for multiple testing. Both Aβ
peptides showed a nominal significant negative correlation with
mean diffusivity in the cingulum bundles and corticospinal
tract. There was also a nominal significant negative correlation
for CSF Aβ42 and radial diffusivity, but a positive correlation
with fractional anisotropy in the cingulum bundles. Comparing
the two Aβ peptides, the positive correlation with fractional
TABLE 5 | Correlations between CSF Aβ43, CSF Aβ42, and diffusion tensor imaging metrics in the selected tracts.
Unadjusted Adjusted for age
Aβ43 Aβ42 p Aβ43 Aβ42 p
FA Cingulum 0.35∗ 0.53∗∗ 0.007∗ 0.18 0.40∗ 0.01∗
FA Corticospinal 0.11 0.17 – −0.10 −0.06 –
FA Callosum-Forceps 0.21 0.30∗ – −0.02 0.06 –
FA Uncinate fasciculus −0.02 0.01 – −0.19 −0.18 –
DR Cingulum −0.43∗∗ −0.55∗∗ – −0.25 −0.39∗ –
DR Corticospinal −0.29∗ −0.32∗ – −0.11 −0.12 –
DR Callosum-Forceps −0.29∗ −0.33∗ – −0.07 −0.10 –
DR Uncinate fasciculus −0.04 −0.03 – 0.18 0.23 –
DA Cingulum −0.40∗ −0.32∗ – −0.27 0.16 –
DA Corticospinal −0.36∗ −0.34∗ – −0.43∗∗ −0.42∗∗ –
DA Callosum-Forceps −0.36∗ −0.34∗ – −0.24 −0.21 –
DA Uncinate fasciculus −0.28 −0.23 – −0.09 0.004 –
MD Cingulum −0.45∗∗ −0.52∗∗ – −0.30∗ −0.37∗ –
MD Corticospinal −0.44∗∗ −0.41∗∗ – −0.34∗ −0.30∗ –
MD Callosum-Forceps −0.31∗ −0.34∗ – −0.11 −0.12 –
MD Uncinate fasciculus −0.13 −0.10 – 0.10 0.17 –
Data presented are Spearman’s rank coefficients for bivariate correlation and partial correlation correcting for age, and significant p-values for the test of difference
between the correlation coefficients for CSF Aβ43 and Aβ42. Diffusion tensor imaging measurements were missing for one subject, n = 49. FA, fractional anisotropy; DR,
radial diffusivity; DA; axial diffusivity, MD; mean diffusivity. ∗Nominal significance (p < 0.05), ∗∗Significance with Bonferroni correction for multiple testing (p < 0.05/16).
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anisotropy in the cingulum bundles was slightly stronger for
CSF Aβ42 compared to CSF Aβ43, though it did not reach
significance after strict Bonferroni correction for multiple testing
(Table 5).
Cortical Glucose Metabolism
As the 18F-FDG PET scans were obtained on different scanners
in the two cohorts, the data were analyzed in each cohort
separately. There were no significant differences in overall 18F-
FDG SUVR between the SCD and MCI groups and adjustment
for age did not change this. There were no significant correlations
between 18F-FDG SUVRs and either CSF Aβ43 or CSF Aβ42
in Cohort 1 (n = 28). In the larger Cohort 2 (n = 50) both
CSF Aβ43 and Aβ42 appeared to be correlated with glucose
metabolism in the hippocampus and several of the cortical
ROIs, but this changed after correction for the effect of age
when only the correlation between CSF Aβ42 and 18F-FDG
uptake in the entorhinal cortex was significant after correction
for multiple testing. Looking at the SCD and MCI subjects
separately, the correlation between CSF Aβ43 and 18F-FDG
uptake in the posterior cingulate cortex was nominally significant
after correction for age, while the only significant correlation
after correction for multiple testing was that between CSF
Aβ42 and 18F-FDG uptake in the posterior cingulate cortex
in the MCI group (Table 6). By direct comparison none of
the differences in correlation coefficients between CSF Aβ42
and Aβ43 were statistically significant. Unadjusted there was
an inverse relation between p-tau and overall 18F-FDG uptake
(average of the seven ROIs), but after correction for age
there were no significant correlations with either p-tau or
t-tau.
DISCUSSION
The interest in CSF Aβ43 as a biomarker first arose from
experimental data suggesting that this peptide could be more
prone to aggregation than Aβ42, and thus potentially have
importance for amyloidogenesis in AD (Saito et al., 2011; Zou
et al., 2013; Conicella and Fawzi, 2014; Burnouf et al., 2015). Our
results show that CSF Aβ43 levels are inversely correlated with
cortical amyloid deposits, even at the stage of SCD and before
extensive amyloid pathology is evident. However, results revealed
nothing to support the hypothesis that the amyloidogenic impact
of Aβ43 is different to that of Aβ42. The strength of the
correlation between CSF Aβ42 and amyloid load was comparable
in the present study to that reported in other studies (Jagust et al.,
2009; Tolboom et al., 2009; Landau et al., 2013; Palmquist et al.,
2014). Investigating the potential role of CSF Aβ43 in very early
AD pathology is difficult. It has been suggested that CSF Aβ42
levels start to drop prior to the increase in amyloid tracer uptake
(Fagan et al., 2006; Mattsson et al., 2015), but contradictory
results have also been presented (Landau et al., 2013). 18F-FLUT
only binds Aβ when it has formed extensive β-sheet formations
in insoluble fibrils, and does not bind to the soluble Aβ oligomers
that are suggested more likely to be the main neurotoxic culprit
in AD (Selkoe and Hardy, 2016). Whether Aβ43 in CSF may
have an impact on the quantity and toxicity of oligomers cannot
be answered by the current imaging techniques. Recently, the
first successful use of a monoclonal antibody-based PET ligand,
capable of binding soluble Aβ protofibrils, was demonstrated in
two AD mouse models (Sehlin et al., 2016). Future use of similar
radioligands in humans could possibly elucidate the impact on
oligomers.
TABLE 6 | Correlations between CSF Aβ43, CSF Aβ42, and 18F-FDG SUVRs in Cohort 2.
All SCD n = 11 MCI n = 39
Aβ43 Aβ42 Aβ43 Aβ42 Aβ43 Aβ42
Hippocampus 0.32∗ 0.42∗∗ 0.37 0.53 0.35∗ 0.43∗∗
Age-adjusted 0.12 0.22 0.39 0.54 0.01 0.08
Entorhinal 0.35∗ 0.47∗∗ 0.26 0.60 0.34∗ 0.43∗∗
Age-adjusted 0.25 0.38∗∗ 0.29 0.60 0.14 0.24
Posterior cingulate 0.40∗∗ 0.53∗∗ 0.08 0.30 0.61∗∗ 0.69∗∗
Age-adjusted 0.16 0.31∗ 0.05 0.30 0.37∗ 0.46∗∗
Temporopolar 0.28 0.36∗ 0.22 0.48 0.22 0.31
Age-adjusted 0.14 0.23 0.26 0.49 −0.03 0.05
Middle temporal 0.37∗ 0.44∗∗ 0.13 0.31 0.40∗ 0.46∗∗
Age-adjusted 0.16 0.24 0.16 0.31 0.10 0.14
Inferior parietal 0.42∗∗ 0.50∗∗ 0.27 0.42 0.51∗∗ 0.56∗∗
Age-adjusted 0.19 0.27 0.30 0.42 0.22 0.24
Inferior frontal 0.25 0.37∗ 0.06 −0.01 0.38∗ 0.50∗∗
Age-adjusted −0.05 0.09 0.06 −0.01 −0.02 0.13
Average of all six cortical ROIs 0.41∗∗ 0.51∗∗ 0.07 0.35 0.48∗∗ 0.55∗∗
Age-adjusted 0.21 0.31∗ 0.09 0.35 0.19 0.26
Data presented are Spearman’s rank correlation coefficients for bivariate correlations and partial correlations controlling for age. ∗Nominal significance (p < 0.05),
∗∗Significance with Bonferroni correction for multiple testing (p < 0.05/7). None of the differences in correlations coefficients between CSF Aβ43 and Aβ42 were statistically
significant.
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Measurements of Aβ43 in CSF have not previously been
described in relation to cerebral imaging findings, while CSF
Aβ42 has been extensively studied. CSF Aβ42 has been shown
previously to correlate with hippocampal volume in several
cross-sectional studies (Apostolova et al., 2010; Wang et al.,
2015). Some longitudinal studies have reported no association
between CSF Aβ42 and hippocampal volume at baseline, but
an association with subsequent hippocampal atrophy (Schuff
et al., 2009; Tosun et al., 2010; Stricker et al., 2012; Mattsson
et al., 2014). Other studies have shown no association either at
baseline (de Souza et al., 2012) or longitudinally (Henneman
et al., 2009; Tarawneh et al., 2015). One explanation for the
inconsistency is that the rates of alteration of analytes in CSF
and imaging biomarkers are neither parallel nor linear. As a
result the correlations between biomarkers will change over time
with disease progression (Insel et al., 2016). Divergences in how
the various disease stages are defined will further contribute to
this variability. We found that the correlation with hippocampal
volume tended to be stronger in the SCD group in Cohort 2,
especially for CSF Aβ43. Previous studies have shown that brain
amyloid load is related to hippocampal volume in cognitively
healthy elderly (Dickerson et al., 2009) and in SCD, but not
in MCI and AD (Bourgeat et al., 2010; Chételat et al., 2010a).
Similarly, Fagan et al. (2009) found that CSF Aβ42 correlated
with whole-brain volume in elderly subjects without cognitive
impairment, but not in MCI and AD, suggesting that the
association between atrophy and amyloid could be present only
early in the disease process. Many studies have described a strong
correlation between CSF tau and hippocampal atrophy in MCI
and AD (Henneman et al., 2009; Apostolova et al., 2010; de Souza
et al., 2012; Tarawneh et al., 2015). In the current study, we found
that hippocampal volume was better predicted by either CSF
Aβ43 or Aβ42 than by t-tau or p-tau, which is in line with former
studies in SCD and healthy elderly individuals. That the result
differs from past reports in patients with MCI may possibly be
attributed to the younger age of our MCI subjects compared to
many of the previously published MCI cohorts.
White matter changes are also known to be related to
CSF biomarkers (Amlien and Fjell, 2014). CSF Aβ42 has been
shown to be positively associated with fractional anisotropy and
inversely with mean diffusivity (Gold et al., 2014; Li et al., 2014)
as found also in the current study. Both DTI and 18F-FLUT PET
have been reported to be superior to the core CSF biomarkers in
predicting the conversion from MCI to dementia (Selnes et al.,
2013; Shaffer et al., 2013; Perani et al., 2016). Therefore, it was
particularly interesting to compare these biomarkers with CSF
Aβ43 that in a previous study was suggested to have the same
quality. Surprisingly, fractional anisotropy in the cingulum fibers
appeared to be better correlated with CSF Aβ42 than Aβ43 and
the trend was the same for cortical glucose metabolism.
The current study has several limitations. The use of
different MRI and PET-scanners in the two cohorts made direct
comparisons between cohorts challenging. Cortical thickness
was measured to be higher in Cohort 2 than in Cohort 1
for several of the ROIs even though p-tau levels were on
average higher in Cohort 2. Correcting for age resulted in only
a slight reduction in the between cohort differences in these
ROIs. It is known that differences in scanner field strength and
possibly also scanner settings like pulse sequence, can impact
on regional cortical thickness measurements (Han et al., 2006;
Govindarajan et al., 2014; McCarthy et al., 2015), which may have
contributed to the described differences between the cohorts.
The cortical thickness measures were obtained by automated
segmentation using the freely available and widely used software
FreeSurfer. FreeSurfer version, operating system and workstation
used in the processing can also impact the cortical thickness
measurements (Gronenschild et al., 2012), but were identical for
the two cohorts in this study. Some have suggested that there
could be a transitional phase in the development of AD with
increased thickness of certain cortical areas (Chételat et al., 2010b;
Fortea et al., 2011; Molinuevo et al., 2012), but this has mainly
been described in pre-clinical stages. Because we suspected a
significant scanner effect, the imaging data were analyzed in
each cohort separately, with a lower number of subjects in each
analysis as a consequence. The cohorts came from somewhat
different populations; all subjects in Cohort 2 were consecutively
recruited from a memory clinic, while Cohort 1 also included
subjects recruited by advertisements. Greater variability due to
partly community based recruitment and fewer subjects with
abnormal CSF biomarkers could be the reason why no correlation
with neurodegenerative imaging biomarkers was found in Cohort
1. The study is also limited by the fact that we only included
subjects that had already developed cognitive symptoms (which
are only subjective in the case of SCD). We could therefore
not assess CSF Aβ43 in pre-clinical stages of AD such as in
cognitively normal subjects with positive 18F-FLUT PET, nor
could we evaluate the impact of biomarkers on the distinction
between controls and SCD. This ought to be assessed in future
studies.
CONCLUSION
In this first description of CSF Aβ43 in relation to imaging
biomarkers, we found that CSF levels of Aβ43 are inversely
correlated with fibrillary Aβ accumulation in the brain
and more weakly positively correlated with biomarkers of
neurodegeneration including hippocampal volume. However,
none of the studied correlations between CSF Aβ and imaging
measurements were significantly different between the two Aβ
peptides when controlling for multiple testing. We conclude that
in respect to imaging, CSF Aβ43 does not appear to contribute
any added value over the well-established CSF biomarker Aβ42
in distinguishing individuals with SCD from those with MCI.
AUTHOR CONTRIBUTIONS
IA planned the study, recruited and clinically examined study
participants, performed the statistical analyses and wrote the
manuscript. CL planned the study and performed ELISA of
CSF Aβ43 together with IM. PS and LK processed the MRI
and 18F-FDG PET images and performed clinical examinations
of participants. CC processed the 18F-FLUT PET images. BG
visually interpreted 18F-FDG and 18F-FLUT PET scans. MW
Frontiers in Aging Neuroscience | www.frontiersin.org 10 February 2017 | Volume 9 | Article 9
fnagi-09-00009 February 3, 2017 Time: 13:22 # 11
Almdahl et al. CSF Aβ43 Relation to Imaging
carried out laboratory work and administered the CSF biobank.
RG did neuropsychological assessments of participants. AB
supervised imaging acquisition. LW, SS, GB, and TF supervised
the project. All authors critically revised and approved the
manuscript.
FUNDING
This study is part of a cross-regional collaboration, Dementia
Disease Initiation (DDI), and is supported by a grant from
the Research Council of Norway (NASATS-NevroNor grant
217780/H10).
ACKNOWLEDGMENTS
The authors thank all the participants in the DDI and MCI
projects at Akershus University Hospital for their invaluable
contribution and study nurse Erna Utnes for her effort in
collecting study data and caring for the participants.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fnagi.
2017.00009/full#supplementary-material
REFERENCES
Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H.,
Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment
due to Alzheimer’s disease: recommendations from the National Institute
on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement. 7, 270–279. doi: 10.1016/j.jalz.2011.
03.008
Amlien, I. K., and Fjell, A. M. (2014). Diffusion tensor imaging of white
matter degeneration in Alzheimer’s disease and mild cognitive impairment.
Neuroscience 276, 206–215. doi: 10.1016/j.neuroscience.2014.02.017
Apostolova, L. G., Hwang, K. S., Andrawis, J. P., Green, A. E., Babakchanian, S.,
Morra, J. H., et al. (2010). 3D PIB and CSF biomarker associations with
hippocampal atrophy in ADNI subjects. Neurobiol. Aging 31, 1284–1303. doi:
10.1016/j.neurobiolaging.2010.05.003
Benton, A. L., and Hamsher, K. (1989). Multilingual Aphasia Examination. Iowa
City, IA: AJA Associates.
Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J., and Vanmechelen, E.
(1995). Tau protein in cerebrospinal fluid: a biochemical marker for axonal
degeneration?in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231–245.
Bourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K.,
et al. (2010). Beta-amyloid burden in the temporal neocortex is related to
hippocampal atrophy in elderly subjects without dementia. Neurology 74,
121–127. doi: 10.1212/WNL.0b013e3181c918b5
Bruggink, K. A., Kuiperij, H. B., Claassen, J. A., and Verbeek, M. M. (2013). The
diagnostic value of CSF amyloid-β43 in differentiation of dementia syndromes.
Curr. Alzheimer Res. 10, 1034–1040. doi: 10.2174/15672050113106660168
Burnouf, S., Gorsky, M. K., Dols, J., Grönke, S., and Partridge, L. (2015). Aβ43
is neurotoxic and primes aggregation of Aβ40 in vivo. Acta Neuropathol. 130,
35–47. doi: 10.1007/s00401-015-1419-y
Chemuru, S., Kodali, R., and Wetzel, R. (2016). C-Terminal threonine reduces
Aβ43 amyloidogenicity compared with Aβ42. J. Mol. Biol. 428, 274–291. doi:
10.1016/j.jmb.2015.06.008
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D.,
et al. (2010a). Relationship between atrophy and beta-amyloid deposition in
Alzheimer disease. Ann. Neurol. 67, 317–324. doi: 10.1002/ana.21955
Chételat, G., Villemagne, V. L., Pike, K. E., Baron, J. C., Bourgeat, P., Jones, G., et al.
(2010b). Larger temporal volume in elderly with high versus low beta-amyloid
deposition. Brain 133, 3349–3358. doi: 10.1093/brain/awq187
Coello, C., Willoch, F., Selnes, P., Gjerstad, L., Fladby, T., and Skretting, A.
(2013). Correction of partial volume effect in (18)F-FDG PET brain studies
using coregistered MR volumes: voxel based analysis of tracer uptake in
the white matter. Neuroimage 72, 183–192. doi: 10.1016/j.neuroimage.2013.
01.043
Conicella, A. E., and Fawzi, N. L. (2014). The C-terminal threonine of Aβ43
nucleates toxic aggregation via structural and dynamical changes in monomers
and protofibrils. Biochemistry 53, 3095–3105. doi: 10.1021/bi500131a
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D.,
et al. (2006). An automated labeling system for subdividing the human cerebral
cortex on MRI scans into gyral based regions of interest. Neuroimage 31,
968–980.
de Souza, L. C., Chupin, M., Lamari, F., Jardel, C., Leclercq, D., Colliot, O.,
et al. (2012). CSF tau markers are correlated with hippocampal volume
in Alzheimer’s disease. Neurobiol. Aging 33, 1253–1257. doi: 10.1016/j.
neurobiolaging.2011.02.022
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N.,
et al. (2009). The cortical signature of Alzheimer’s disease: regionally specific
cortical thinning relates to symptom severity in very mild to mild AD dementia
and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex
19, 497–510. doi: 10.1093/cercor/bhn113
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C.,
et al. (2009). Decreased CSF Aβ42 correlates with brain atrophy in cognitively
normal elderly. Ann. Neurol. 65, 176–183. doi: 10.1002/ana.21559
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y., Dence, C. S., Shah, A. R.,
et al. (2006). Inverse relation between in vivo amyloid imaging load and
cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 59, 512–519. doi: 10.1002/
ana.20730
Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L. O., Sarria, A., and
Serrano-Aguilar, P. (2014). Meta-review of CSF core biomarkers in Alzheimer’s
disease: the state-of-the-art after the new revised diagnostic criteria. Front.
Aging Neurosci. 6:47. doi: 10.3389/fnagi.2014.00047
Fillenbaum, G. G., van Belle, G., Morris, J. C., Mohs, R. C., Mirra, S. S., Davis,
P. C., et al. (2008). Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD): the first twenty years. Alzheimers Dement. 4, 96–109. doi: 10.1016/j.
jalz.2007.08.005
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., et al.
(2002). Whole brain segmentation: automated labeling of neuroanatomical
structures in the human brain. Neuron 33, 341–355.
Fischl, B., Stevens, A. A., Rajendran, N., Yeo, B. T., Greve, D. N., Van Leemput, K.,
et al. (2009). Predicting the location of entorhinal cortex from MRI. Neuroimage
47, 8–17. doi: 10.1016/j.neuroimage.2009.04.033
Fischl, B., van der Kouwe, A., Destrieux, C., Halgren, E., Ségonne, F., Salat, D. H.,
et al. (2004). Automatically parcellating the human cerebral cortex. Cereb.
Cortex 14, 11–22.
Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). Mini-mental state.
A practical method for grading the cognitive state of patients for the clinician.
J. Psychiatr. Res. 12, 189–198. doi: 10.1016/0022-3956(75)90026-6
Fortea, J., Sala-Llonch, R., Bartrés-Faz, D., Lladó, A., Solé-Padullés, C., Bosch, B.,
et al. (2011). Cognitively preserved subjects with transitional cerebrospinal fluid
β-amyloid 1-42 values have thicker cortex in Alzheimer’s disease vulnerable
areas. Biol. Psychiatry 70, 183–190. doi: 10.1016/j.biopsych.2011.02.017
Fouquet, M., Desgranges, B., Landeau, B., Duchesnay, E., Mezenge, F., Sayette, V.,
et al. (2009). Longitudinal brain metabolic changes from amnestic mild
cognitive impairment to Alzheimer’s disease. Brain 132, 2058–2067. doi: 10.
1093/brain/awp132
Gold, B. T., Zhu, Z., Brown, C. A., Andersen, A. H., LaDu, M. J., Tai, L., et al.
(2014). White matter integrity is associated with cerebrospinal fluid markers
of Alzheimer’s disease in normal adults. Neurobiol. Aging 35, 2263–2271. doi:
10.1016/j.neurobiolaging.2014.04.030
Govindarajan, K. A., Freeman, L., Cai, C., Rahbar, M. H., and Narayana, P. A.
(2014). Effect of intrinsic and extrinsic factors on global and regional cortical
thickness. PLoS ONE 9:e96429. doi: 10.1371/journal.pone.0096429
Frontiers in Aging Neuroscience | www.frontiersin.org 11 February 2017 | Volume 9 | Article 9
fnagi-09-00009 February 3, 2017 Time: 13:22 # 12
Almdahl et al. CSF Aβ43 Relation to Imaging
Gronenschild, E. H., Habets, P., Jacobs, H. I., Mengelers, R., Rozendaal, N.,
van Os, J., et al. (2012). The effects of FreeSurfer version, workstation
type, and Macintosh operating system version on anatomical volume and
cortical thickness measurements. PLoS ONE 7:e38234. doi: 10.1371/journal.
pone.0038234
Han, X., Jovicich, K., Salat, D., van der Kouwe, A., Quinn, B., Czanner, S., et al.
(2006). Reliability of MRI-derviced measurements of human cerebral thickness:
the effect of field strength, scanner upgrade and manufacturer. Neuroimage 32,
180–194. doi: 10.1016/j.neuroimage.2006.02.051
Henneman, W. J. P., Vrenken, H., Barnes, J., Sluimer, I. C., Verwey, N. A.,
Blankenstein, M. A., et al. (2009). Baseline CSF p-tau levels independently
predict progression of hippocampal atrophy in Alzheimer disease. Neurology
73, 935–940. doi: 10.1212/WNL.0b013e3181b879ac
Insel, P. S., Mattson, N., Mackin, R. S., Schöll, M., Nosheny, R. L., Tosun, D.,
et al. (2016). Accelerating rates of cognitive decline and imaging markers
associated with β-amyloid pathology. Neurology 86, 1887–1896. doi: 10.1212/
WNL.0000000000002683
Iizuka, T., Shoji, M., Harigaya, Y., Kawarabayashi, T., Watanabe, M., Kanai, M.,
et al. (1995). Amyloid beta-protein ending at Thr43 is a minor component
of some diffuse plaques in the Alzheimer’s disease brain, but is not found in
cerebrovascular amyloid. Brain Res. 702, 275–278.
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C.,
Tsopelas, N. D., et al. (2008). Post-mortem correlates of in vivo PiB-PET
amyloid imaging in a typical case of Alzheimer’s disease. Brain 131, 1630–1645.
doi: 10.1093/brain/awn016
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman,
E. M., et al. (2009). Relationships between biomarkers in aging and dementia.
Neurology 73, 1193–1199. doi: 10.1212/WNL.0b013e3181bc010c
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G.,
et al. (2014). A conceptual framework for research on subjective cognitive
decline in preclinical Alzheimer’s disease. Alzheimers Dement. 10, 844–852.
doi: 10.1016/j.jalz.2014.01.001
Kakuda, N., Shoji, M., Arai, H., Furukawa, K., Ikeuchi, T., Akazawa, K.,
et al. (2012). Altered γ-secretase activity in mild cognitive impairment and
Alzheimer’s disease. EMBO Mol. Med. 4, 344–352. doi: 10.1002/emmm.2012
00214
Kalheim, L. F., Bjørnerud, A., Fladby, T., Vegge, K., and Selnes, P. (2016). White
matter hyperintensity microstructure in amyloid dysmetabolism. J. Cereb. Blood
Flow Metab. doi: 10.1177/0271678X15627465 [Epub ahead of print].
Kandimalla, R. J., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Gupta, N.,
Sharma, D. R., et al. (2011). Apo-Eε4 allele in conjunction with Aβ42 and tau
in CSF: biomarker for Alzheimer’s disease. Curr. Alzheimer Res. 8, 187–196.
doi: 10.2174/156720511795256071
Kandimalla, R. J., Prabhakar, S., Wani, W. Y., Kaushal, A., Gupta, N., Sharma, D. R.,
et al. (2013). CSF levels in the prediction of Alzheimer’s disease. Biol. Open 2,
1119–1124. doi: 10.1242/bio.20135447
Keller, L., Welander, H., Chiang, H. H., Tjernberg, L. O., Nennesmo, I., Wallin,
A. K., et al. (2010). The PSEN1 I143T mutation in a Swedish family with
Alzheimer’s disease: clinical report and quantification of Aβ in different brain
regions. Eur. J. Hum. Genet. 18, 1202–1208. doi: 10.1038/ejhg.2010.107
Kiernan, R. J., Mueller, J., Langston, J. W., and Van Dyke, C. (1987). The
neurobehavioral cognitive status examination: a brief but quantitative approach
to cognitive assessment. Ann. Intern. Med. 107, 481–485.
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., and
Trojanowski, J. Q. (2013). Comparing positron emission tomography imaging
and cerebrospinal fluid measurements of β-amyloid. Ann. Neurol. 74, 826–836.
Lauridsen, C., Sando, S. B., Shabnam, A., Møller, I., Berge, G., Grøntvedt, G. R.,
et al. (2016). Cerebrospinal fluid levels of amyloid beta 1-43 in patients with
amnestic mild cognitive impairment or early Alzheimer’s disease: a 2-year
follow-up study. Front. Aging Neurosci. 8:30. doi: 10.3389/fnagi.2016.00030
Lee, I. A., and Preacher, K. J. (2013). Calculation for the Test of the Difference
between Two Dependent Correlations with One Variable in Common [Computer
Software]. Available at: http://quantpsy.org
Lee, S. H., Coutu, J. P., Wilkens, P., Yendiki, A., Rosas, H. D., Salat, D. H.,
et al. (2015). Tract-based analysis of white matter degeneration in Alzheimer’s
disease. Neuroscience 301, 79–89. doi: 10.1016/j.neuroscience.2015.05.049
Li, Q. X., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S.,
et al. (2015). Alzheimer’s disease normative cerebrospinal fluid biomarkers
validated in PET amyloid-β characterized subjects from the Australian Imaging,
Biomarkers and Lifestyle (AIBL) study. J. Alzheimers Dis. 48, 175–187. doi:
10.3233/JAD-150247
Li, X., Li, T. Q., Andreasen, N., Wiberg, M. K., Westman, E., and Wahlund,
L. O., (2014). The association between biomarkers in cerebrospinal fluid and
structural changes in the brain in patients with Alzheimer’s disease. J. Intern.
Med. 275, 418–427. doi: 10.1111/joim.12164
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W., Shaw, L. M.,
et al. (2015). Independent information from cerebrospinal fluid amyloid-β and
florbetapir imaging in Alzheimer’s disease. Brain 138, 772–783. doi: 10.1093/
brain/awu367
Mattsson, N., Insel, P., Nosheny, R., Trojanowski, J. Q., Shaw, L. M., Jack, C. R.,
et al. (2014). Effects of CSF proteins on brain atrophy rates in cognitively healthy
older adults. Neurobiol. Aging 35, 614–622. doi: 10.1016/j.neurobiolaging.2013.
08.027
McCarthy, C. S., Ramprashad, A., Thompson, C., Botti, J. A., Coman, I. L., and
Kates, W. R. (2015). A comparison of FreeSurfer-generated data with and
without manual intervention. Front. Neurosci. 9:379. doi: 10.3389/fnins.2015.
00379
Miravalle, L., Calero, M., Takao, M., Roher, A. E., Ghetti, B., and Vidar, R. (2005).
Amino-terminally truncated Abeta peptide species are the main component of
cotton wool plaques. Biochemistry 44, 10810–10821.
Molinuevo, J. L., Sánches-Valle, R., Lladó, A., Fortea, J., Bartrés-Faz, D., and
Rami, L. (2012). Identifying earlier Alzheimer’s disease: insights from the
preclinical and prodromal phases. Neurodegener. Dis. 10, 158–160. doi: 10.1159/
000332806
Morris, J. C. (1997). Clinical dementia rating: a reliable and valid diagnostic and
staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 9(Suppl.
1), 173–176; discussion 177–178.
Nakaya, Y., Yamane, T., Shiraishi, H., Wang, H. Q., Matsubara, E., Sato, T.,
et al. (2005). Random mutagenesis of presenilin-1 identifies novel mutants
exclusively generating long amyloid beta-peptides. J. Biol. Chem. 280,
19070–19077.
Palmquist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks,
D. J., et al. (2014). Accuracy of brain amyloid detection in clinical practice
using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid
positron emission tomography. JAMA Neurol. 71, 1282–1289. doi: 10.1001/
jamaneurol.2014.1358
Parvathy, S., Davies, P., Haroutunian, V., Purohit, D. P., Davis, K. L., Mohs, R. C.,
et al. (2001). Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing
amyloid plaques and cognitive decline. Arch. Neurol. 58, 2025–2031. doi: 10.
1001/archneur.58.12.2025
Perani, D., Cerami, C., Caminiti, S. P., Santangelo, R., Coppi, E., Ferrari, L., et al.
(2016). Cross-validation of biomarkers for the early differential diagnosis and
prognosis of dementia in a clinical setting. Eur. J. Nucl. Med. Mol. Imaging 43,
499–508. doi: 10.1007/s00259-015-3170-y
Reitan, R. M., and Wolfson, D. (1985). The Halstead-Reitan Neuropsychological Test
Battery. Tucson, AZ: Neuropsychology Press.
Royall, D. R., Mahurin, R. K., and Gray, K. F. (1992). Bedside assessment of
executive cognitive impairment: the executive interview. J. Am. Geriatr. Soc. 40,
1221–1226.
Sabuncu, M. R., Desikan, R. S., Sepulcre, J., Yeo, B. T., Liu, H., Schmansky, N. J.,
et al. (2011). The dynamics of cortical and hippocampal atrophy in Alzheimer
disease. Arch. Neurol. 68, 1040–1048. doi: 10.1001/archneurol.2011.167
Saito, T., Suemoto, T., Brouwers, N., Sleegers, K., Funamoto, S., Mihira, N., et al.
(2011). Potent amyloidogenicity and pathogenicity of Aβ43. Nat. Neurosci. 14,
1023–1032. doi: 10.1038/nn.2858
Sandebring, A., Welander, H., Winblad, B., Gra, C., and Tjernberg, L. O. (2013).
The pathogenic Aβ43 is enriched in familial and sporadic Alzheimer disease.
PLoS ONE 8:e55847. doi: 10.1371/journal.pone.0055847
Schmidt, M. (1996). Rey Auditory and Verbal Learning Test. A Handbook. Los
Angeles, CA: Western Psychological Services.
Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q.,
et al. (2009). Alzheimer’s Disease Neuroimaging Initiative. MRI of hippocampal
volume loss in early Alzheimer’s disease in relation to ApoE genotype and
biomarkers. Brain 132, 1067–1077. doi: 10.1093/brain/awp007
Sehlin, D., Fang, X. T., Cato, L., Antoni, G., Lannfelt, L., and Syvänen, S.
(2016). Antibody-based PET imaging of amyloid beta in mouse models
Frontiers in Aging Neuroscience | www.frontiersin.org 12 February 2017 | Volume 9 | Article 9
fnagi-09-00009 February 3, 2017 Time: 13:22 # 13
Almdahl et al. CSF Aβ43 Relation to Imaging
of Alzheimer’s disease. Nat. Commun. 7:10759. doi: 10.1038/ncomms
10759
Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease
at 25 years. EMBO Mol. Med. 8, 595–608. doi: 10.15252/emmm.201606210
Selnes, P., Aarsland, D., Bjørnerud, A., Gjerstad, L., Wallin, A., Hessen, E., et al.
(2013). Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of
cognitive decline and medial temporal lobe atrophy in subjective cognitive
impairment and mild cognitive impairment. J. Alzheimers Dis. 33, 723–736.
doi: 10.3233/JAD-2012-121603
Shaffer, J. L., Petrella, J. R., Sheldon, F. C., Choudhury, K. R., Calhoun, V. D.,
and Coleman, R. E. (2013). Predicting cognitive decline in subjects at risk for
Alzheimer disease by using combined cerebrospinal fluid, MR imaging and PET
biomarkers. Radiology 266, 583–591. doi: 10.1148/radiol.12120010
Shimojo, M., Sahara, N., Mizoroki, T., Funamoto, S., Morishima-Kawashima, M.,
Kudo, T., et al. (2008). Enzymatic characteristics of I213T mutant Presenilin-
1/γ-secretase in cell models and knock-in mouse brains. FAD-linked mutation
impairs γ-site cleavage of APP-CTFβ. J. Biol. Chem. 283, 16488–16496. doi:
10.1074/jbc.M801279200
Sjögren, M., Vanderstichele, H., Agren, H., Zachrisson, O., Edsbagge, M., Wikkelsø,
C., et al. (2001). Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-
93 years of age: establishment of reference values. Clin. Chem. 47, 1776–1781.
Stricker, N. H., Dodge, H. H., Dowling, N. M., Han, S. D., Erosheva, E. A., and
Jagust, W. J. (2012). CSF biomarker associations with change in hippocampal
volume and precuneus thickness: implications for the Alzheimer’s pathological
cascade. Brain Imaging Behav. 6, 599–609. doi: 10.1007/s11682-012-9171-6
Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M.,
Funamoto, S., et al. (2009). γ-Secretase: successive tripeptide and tetrapeptide
release from the transmembrane domain of β-carboxyl terminal fragment.
J. Neurosci. 29, 13042–13052. doi: 10.1523/JNEUROSCI.2362-09.2009
Tarawneh, R., Head, D., Allison, S., Buckles, V., Fagan, A. M., Ladenson, J. H.,
et al. (2015). Cerebrospinal fluid markers of neurodegeneration and rates of
brain atrophy in early Alzheimer disease. JAMA Neurol. 72, 656–665. doi:
10.1001/jamaneurol.2015.0202
Tolboom, N., van der Flier, W. M., Yaqub, M., Boellaard, R., Verwey, N. A.,
Blankenstein, M. A., et al. (2009). Relationship of cerebrospinal fluid markers to
11C-PiB and 18F-FDDNP binding. J. Nucl. Med. 50, 1464–1470. doi: 10.2967/
jnumed.109.064360
Tosun, D., Schuff, N., Truran-Sacrey, D., Shaw, L. M., Trojanowski, J. Q., Aisen, P.,
et al. (2010). Relations between brain tissue loss, CSF biomarkers and the ApoE
genetic profile: a longitudinal MRI study. Neurobiol. Aging 31, 1340–1354.
doi: 10.1016/j.neurobiolaging.2010.04.030
Vandersteen, A., Masman, M. F., De Baets, G., Jonckheere, W., van der Werf, K.,
Marrink, S. J., et al. (2012). Molecular plasticity regulates oligomerization and
cytotoxicity of the multipeptide-length amyloid-β peptide pool. J. Biol. Chem.
287, 36732–36743. doi: 10.1074/jbc.M112.394635
Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M. A.,
Andreasen, N., et al. (2000). Standardization of measurement of beta-
amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245–258.
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der
Perre, B., Sjögren, M., et al. (2000). Quantification of tau phosphorylated at
threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic
phosphopeptide for standardization. Neurosci. Lett. 285, 49–52.
Vemuri, P., and Jack, C. R. (2010). Role of structural MRI in Alzheimer’s disease.
Alzheimers Res. Ther. 2:23. doi: 10.1186/alzrt47
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner,
M. W., et al. (2009). MRI and CSF biomarkers in normal, MCI and AD subjects:
predicting future clinical change. Neurology 73, 294–301. doi: 10.1212/WNL.
0b013e3181af79e5
Vukovich, R., Perneczky, R., Drzezga, A., Förstl, H., Kurz, A., and
Riemenschneider, M. (2009). Brain metabolic correlates of cerebrospinal
fluid beta-amyloid 42 and tau in Alzheimer’s disease. Dement. Geriatr. Cogn.
Disord. 27, 474–480. doi: 10.1159/000218080
Wang, L., Benzinger, T. L., Hassenstab, J., Blazey, T., Owen, C., Liu, J., et al.
(2015). Spatially distinct atrophy is linked to β-amyloid and tau in preclinical
Alzheimer disease. Neurology 84, 1254–1260. doi: 10.1212/WNL.0000000000
001401
Warrington, E. K., and James, M. (1991). The Visual Object and Space Perception
Battery. Bury St. Edmunds: Thames Valley Test Company.
Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B., and Tjernberg,
L. O. (2009). Aβ43 is more frequent than Aβ42 in amyloid plaque cores from
Alzheimer disease brains. J. Neurochem. 110, 697–706. doi: 10.1111/j.1471-
4159.2009.06170.x
Whitwell, J. L., Shiung, M. M., Przybelski, S. A., Weigand, S. D., Knopman, D. S.,
Boeve, B. F., et al. (2008). MRI patterns of atrophy associated with progression
to AD in amnestic mild cognitive impairment. Neurology 70, 512–520.
Yakushev, I., Muller, M. J., Buchholz, H. G., Lang, U., Rossmann, H., and
Hampel, H. (2012). Stage-dependent agreement between cerebrospinal fluid
proteins and FDG-PET findings in Alzheimer’s disease. Curr. Alzheimer Res.
9, 241–247.
Zou, K., Liu, J., Watanabe, A., Hiraga, S., Liu, S., Tanabe, C., et al. (2013). Aβ43 is the
earliest-depositing Aβ species in APP transgenic mouse brain and is converted
to Aβ41 by two active domains of ACE. Am. J. Pathol. 182, 2322–2331. doi:
10.1016/j.ajpath.2013.01.053
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer IB and handling Editor declared their shared affiliation, and the
handling Editor states that the process nevertheless met the standards of a fair and
objective review.
Copyright © 2017 Almdahl, Lauridsen, Selnes, Kalheim, Coello, Gajdzik, Møller,
Wettergreen, Grambaite, Bjørnerud, Bråthen, Sando, White and Fladby. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 13 February 2017 | Volume 9 | Article 9
